Interaction Checker
No Interaction Expected
Raltegravir (RAL)
Fostemsavir (FTR)
Quality of Evidence: Very Low
Summary:
Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Coadministration of fostemsavir (1200 mg single dose) in 17 individuals on raltegravir treatment (400 mg twice daily) increased temsavir Cmax, AUC and Cmin by 23%, 7% and 17%. When fostemsavir was given twice daily (400 mg twice daily), temsavir Cmax and AUC decreased by 18% and 2% in the presence of raltegravir and tenofovir-DF. These changes are not considered to be clinically significant and do not warrant a dose adjustment.
Description:
View all available interactions with Raltegravir (RAL) by clicking here.
No Version Present
Copyright © 2024 The University of Liverpool. All rights reserved.